US 12,064,434 B2
Ribociclib tablet
Rui Costa, Basel (CH); Arnaud Grandeury, Helfrantzkirch (FR); and Bindhumadhavan Gururajan, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Jun. 8, 2022, as Appl. No. 17/805,956.
Application 17/805,956 is a continuation of application No. 17/003,771, filed on Aug. 26, 2020, abandoned.
Application 17/003,771 is a continuation of application No. 15/564,534, granted, now 10,799,506, issued on Oct. 13, 2020, previously published as PCT/IB2016/052136, filed on Apr. 14, 2016.
Claims priority of provisional application 62/148,240, filed on Apr. 16, 2015.
Prior Publication US 2023/0104792 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/496 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 9/284 (2013.01); A61K 31/496 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A coated pharmaceutical oral tablet comprising ribociclib succinate, the coated pharmaceutical oral tablet comprising a tablet core and a coating, wherein the % of ribociclib succinate (w/w) is at least 50% of the tablet core, and the coating is a polyvinyl alcohol (PVA)-based advanced moisture barrier coating.